3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Vascular Diseases
1
Pathologic Processes
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Liver Neoplasms
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Gliosarcoma
1
Glioblastoma
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Cardiovascular Diseases
1
Carcinoma
1
Blood Protein Disorders
1
Interventions
dacetuzumab
4
tetulomab tetraxetan lu-177
2
Rituximab
2
Lutetium
2
Gemcitabine
2
vandetanib
1
tirbanibulin
1
phenethyl isothiocyanate
1
motesanib diphosphate
1
imetelstat
1
fludarabine
1
ficlatuzumab
1
denileukin diftitox
1
beta-Glucans
1
Nivolumab
1
Lutetium-177
1
Lenalidomide
1
Immunoenzyme Techniques
1
Ganciclovir
1
Erlotinib Hydrochloride
1
Dexamethasone
1
Clofarabine
1
Calcium Dobesilate
1
Bortezomib
1
Bevacizumab
1
Bendamustine Hydrochloride
1
AP 1903 reagent
1
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoproliferative Disorders
×
ficlatuzumab
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled